No, compounded tirzepatide is not going away, but the rules around it have changed. FDA has said the tirzepatide shortage is over. That ended the period when pharmacies could make large batches that copied Zepbound and Mounjaro. A state-licensed 503A pharmacy can still fill a prescription written for one patient. Brand tirzepatide is not going anywhere. If you are new to the drug, start with our tirzepatide guide.
Key takeaways
- Tirzepatide the drug is FDA approved as Mounjaro (type 2 diabetes, NDA 215866) and Zepbound (chronic weight management and obstructive sleep apnea, NDA 217806). Neither is discontinued.
- Compounded tirzepatide is not FDA approved and is not interchangeable with the brands. FDA has said it does not review compounded drugs for safety, effectiveness or quality before they are sold.
- With the shortage resolved, compounding a drug that is essentially a copy of an approved product is restricted. Compounding for an individual patient's documented needs is still permitted for 503A pharmacies.
- The same pattern applies to compounded semaglutide.
- FormBlends works only through prescriptions from independent, state-licensed clinicians and state-licensed 503A compounding pharmacies; availability for your address is confirmed before any charge.
What changed when the shortage ended
Federal law lets a pharmacy compound a drug for one patient when a licensed prescriber decides that patient needs it. While an approved drug is on FDA's shortage list, the rules loosen. Compounders can then make copies of the approved drug to fill the gap. When FDA says the shortage is over, that allowance ends. FDA's compounding questions and answers page explains the framework. The short version is in the table.
| Question | During the FDA shortage | After FDA declared it resolved |
|---|---|---|
| Can compounders make a copy of Zepbound or Mounjaro? | Yes, to address the shortage | Not as a routine copy of the approved product |
| Can a 503A pharmacy compound tirzepatide for one patient with a prescription? | Yes | Yes, when the prescriber documents a patient-specific need |
| Is the compounded product FDA approved? | No | No |
| Is brand tirzepatide available? | Limited supply | Yes, including Lilly's self-pay vials |
Source: FDA, Compounding and the FDA: Questions and Answers; FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
We have deliberately not printed the shortage dates here, because they fall outside the verified facts this page is built on. FDA's drug shortage database is the place to confirm them. Our tirzepatide shortage status page tracks the current position.
Is tirzepatide going away or discontinued?
No. This is the most common confusion in searches like "tirzepatide no longer available." The approved products are on the market. Zepbound was approved for chronic weight management on November 8, 2023, and for obstructive sleep apnea on December 20, 2024. Mounjaro was approved for type 2 diabetes on May 13, 2022. Both come in six strengths from 2.5 to 15 mg. Lilly publishes self-pay vial prices through LillyDirect: $299 a month for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, and $699 for 10, 12.5 and 15 mg. People with commercial insurance that covers Zepbound may pay as little as $25 a month with the savings card.
Get compounded tirzepatide, first month $149, then $239 per month, or $214 per month with Subscribe & Save
Free provider review, personalized dosing, and ongoing support included.
Start Free Assessment →Is compounded semaglutide going away?
The same framework applies. FDA declared the semaglutide shortage resolved as well, so routine copies of Wegovy and Ozempic are restricted while patient-specific 503A compounding continues under a prescription. Compounded semaglutide is not FDA approved and is not interchangeable with Wegovy or Ozempic. If you are choosing between the two compounded drugs, the head-to-head trial evidence favors tirzepatide for weight loss: SURMOUNT-5 reported -20.2% with tirzepatide versus -13.7% with semaglutide at 72 weeks in adults with obesity. See our semaglutide versus tirzepatide comparison for the details.
What "patient-specific" compounding means in practice
A 503A compounding pharmacy fills prescriptions for individual patients. The prescriber decides whether a compounded version is right for you and why. Those reasons are clinical. They belong in your chart, not on a marketing page, so we do not list them here. What you should expect is simple. A licensed clinician assesses you. A prescription is written for you. A state-licensed pharmacy sends a vial with a label that states the ingredients, the concentration and a beyond-use date. Our guide to compounded tirzepatide for weight loss walks through the process.
The risk that grows when supply tightens
FDA has warned about unapproved GLP-1 products sold for weight loss, including products marketed "for research" with no prescription, dosing errors from multi-dose vials, and products whose contents are uncertain. When people hear "compounded tirzepatide is going away," some turn to these sources. That is the wrong direction. A compounded vial dispensed under a prescription by a state-licensed pharmacy, with written mixing and dosing instructions, is a different thing from a gray-market vial. We cover the difference in gray market tirzepatide.
What this means for compounded tirzepatide at FormBlends
FormBlends is Form Blends LLC, a Wyoming limited liability company. Prescriptions are written by independent, state-licensed clinicians (MD, DO, NP or PA) of Recess MD LLC, a separate medical group. Medication is compounded by state-licensed 503A compounding pharmacies. It ships cold-chain with injection supplies included. Lab work is not included. FormBlends has dispensed to 36 states, based on the last 165 shipped orders as of September 5, 2026, and availability for your address is confirmed during the assessment before any charge. If the provider does not prescribe, the charge is refunded.
| FormBlends compounded tirzepatide | Price |
|---|---|
| First month | $149 |
| Then, month to month | $239 a month |
| Subscribe & Save | $214 a month |
| 3-month plan (one-time charge) | $627 |
| 6-month plan (one-time charge) | $1,194 |
| 12-month plan (one-time charge) | $2,148 |
Source: FormBlends pricing, verified September 5, 2026. The price is the same at every dose; shipping is included and lab work is not.
Compounded tirzepatide is not FDA approved and is not interchangeable with Zepbound or Mounjaro. See pricing or begin the assessment at start.
Frequently Asked Questions
Is compounded tirzepatide going away?
Not entirely. Large-batch copies tied to the FDA shortage are no longer permitted now that FDA has declared the shortage resolved. Patient-specific compounding by state-licensed 503A pharmacies, under a clinician's prescription, continues.
Is compounded semaglutide going away?
It follows the same rules. FDA declared the semaglutide shortage resolved, so routine copies are restricted while patient-specific 503A compounding continues. Compounded semaglutide is not FDA approved.
Is tirzepatide being discontinued?
No. Zepbound and Mounjaro remain FDA-approved products in six strengths, and Lilly sells self-pay vials directly. Searches about tirzepatide being "no longer available" usually refer to compounded copies, not the brand.
Will my compounded prescription stop suddenly?
Ask your prescriber and pharmacy directly, because it depends on the prescription and the state. At FormBlends, availability is confirmed for your address during the assessment before any charge, and a refund is issued if the provider does not prescribe.
What should I avoid if compounded supply tightens?
Products sold "for research," with no prescription, or from sellers who will not name a licensed pharmacy. FDA has warned about unapproved GLP-1 products and dosing errors from them. Talk to a clinician about brand options instead.
Sources
- Compounding and the FDA: Questions and Answers, U.S. Food and Drug Administration.
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, U.S. Food and Drug Administration.
- Zepbound (tirzepatide) prescribing information, Eli Lilly via DailyMed, revised 08/2026.
- FDA Approves New Medication for Chronic Weight Management, U.S. Food and Drug Administration, November 8, 2023.
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5), Aronne et al., New England Journal of Medicine, 2025.
- FormBlends pricing, Form Blends LLC, verified September 5, 2026.
Next steps
Read is compounded tirzepatide safe before choosing a source. Browse the tirzepatide hub for every other tirzepatide question. Talk to a clinician about brand or compounded options for your situation. Compounded tirzepatide is not FDA approved and is not interchangeable with Zepbound or Mounjaro; a licensed provider decides whether it is appropriate for you.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →